Neuroscience company Rapport Therapeutics lists on Nasdaq

Rapport Therapeutics expects to raise $154 million from its initial public offering and a concurrent stock sale to private investors, the company announced Thursday evening.

Rapport, a neuroscience biotech backed by Johnson & Johnson, expects to begin trading on Nasdaq on Friday under the ticker $RAPP. The Boston and San Diego-based biotech priced its IPO of 8 million shares at $17 apiece, which translates to $136 million.

Rapport Therapeutics emerged from stealth last year, with plans to study former J&J assets. The company is developing a tablet to treat a form of epilepsy, which it plans to begin studying soon in a Phase 2a trial with adults. It also hopes to develop a long-acting injectable version of the same drug.

Rapport didn’t wait to sell stock to investors. It also announced a sale of…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks